` GTHX (G1 Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

GTHX
vs
S&P 500

Over the past 12 months, GTHX has significantly outperformed S&P 500, delivering a return of 188% compared to the S&P 500's 9% growth.

Stocks Performance
GTHX vs S&P 500

Loading
GTHX
S&P 500
Add Stock

Performance Gap
GTHX vs S&P 500

Loading
GTHX
S&P 500
Difference
www.alphaspread.com

Performance By Year
GTHX vs S&P 500

Loading
GTHX
S&P 500
Add Stock

Competitors Performance
G1 Therapeutics Inc vs Peers

S&P 500
GTHX
ABBV
AMGN
GILD
VRTX
Add Stock

G1 Therapeutics Inc
Glance View

Market Cap
376.8m USD
Industry
Biotechnology

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

GTHX Intrinsic Value
5.49 USD
Overvaluation 23%
Intrinsic Value
Price
Back to Top